
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
New Formulations/Combinations: Oral form of corticosteroid for Tx of mild to moderate Crohn's disease






